RBBP6 通过 JNK 信号通路促进人宫颈癌恶性进展。

RBBP6 promotes human cervical carcinoma malignancy via JNK signaling pathway.

机构信息

Department of Obstetrics and Gynecology, The Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University (Nanjing Maternity and Child Health Care Hospital), Nanjing 210004, China.

Department of Gynecologic Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210094, China.

出版信息

Biomed Pharmacother. 2018 May;101:399-405. doi: 10.1016/j.biopha.2018.02.083. Epub 2018 Mar 22.

DOI:10.1016/j.biopha.2018.02.083

PMID:29501043

Abstract

Previous studies have shown that retinoblastoma binding protein 6 (RBBP6) was overexpressed in malignant tumors and was correlated with poorer prognosis in various cancers. However, its role in cervical carcinoma has not been elucidated. This study was to investigate the relationship between RBBP6 and cervical carcinoma. Cervical carcinoma cell lines SiHa and C33a were used to assess the effect of RBBP6 on cell viability, migration, and proliferation. RBBP6 mRNA and protein levels in cervical cancer tissues increased at least three times as that in the adjacent non-cancerous tissues. Overexpression of RBBP6 in SiHa and C33a cell lines resulted in increased phosphorylated c-Jun NH-terminal kinase (p-JNK) as well as increased cell viability, migration, and proliferation. Moreover, this effect was suppressed by specific JNK inhibitor SP600125. RBBP6 might potentiate cervical carcinoma cell viability, migration and proliferation through JNK signaling pathway. RBBP6 and JNK inhibitor may be beneficial as a novel preventive and therapeutic target for cervical cancer.

摘要

先前的研究表明，视网膜母细胞瘤结合蛋白 6（RBBP6）在恶性肿瘤中过度表达，与多种癌症的预后较差相关。然而，其在宫颈癌中的作用尚未阐明。本研究旨在探讨 RBBP6 与宫颈癌之间的关系。使用宫颈癌细胞系 SiHa 和 C33a 来评估 RBBP6 对细胞活力、迁移和增殖的影响。宫颈癌组织中 RBBP6 的 mRNA 和蛋白水平至少增加了三倍，高于相邻的非癌组织。在 SiHa 和 C33a 细胞系中过表达 RBBP6 导致磷酸化 c-Jun NH2-末端激酶（p-JNK）增加，以及细胞活力、迁移和增殖增加。此外，这种作用被特异性 JNK 抑制剂 SP600125 抑制。RBBP6 可能通过 JNK 信号通路增强宫颈癌细胞的活力、迁移和增殖。RBBP6 和 JNK 抑制剂可能作为宫颈癌的一种新的预防和治疗靶点有益。